Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma

Inclusion Criteria: * Patients with histologically confirmed metastatic melanoma (at stage IIIC or stage IV under the AJCC 2009 classification not surgically resectable. * Patients who do not respond to at least one line of systemic treatment * Male and female (with β-HCG negative test) * Patients HLA-A\*0201 * Age \> 18 years * Blood parameters (Hemoglobin ≥ 10g/dl, Leucocytes ≥ 4000/μl,Lymphocytes ≥ 1000/μl, Platelets ≥100.000/μl, creatinin ≤ 2.0mg/dl, bilirubin ≤ 2.0mg/dl, ASAT and ALAT ≤ 2.5 fold the upper normal level) * OMS performance score \< 3 * Informed written consent. Exclusion Criteria: * Positive serology for HCV, HTLV, HIV, active hepatitis * Protected persons according to French regulations articles L1121-5 to L1121-8 (Public Health Code) * Non-pregnant women without effective contraception * Any serious acute or chronic illness, for example: active infection, coagulation disorder. * Presence of a second cancer in the 5 years preceding inclusion into the study with the exception of in situ cervical carcinoma or a cutaneous carcinoma or other melanoma. * Intercurrent disease requiring corticosteroids. * Any active autoimmune disease including insulin dependent diabetes mellitus. Vitiligo or autoimmune thyroid disease are not criteria for exclusion. * Autoimmune eye disease. * Evidence of immunosuppression for any reason * Primary ocular melanoma * Chemotherapy, immunotherapy or radiotherapy in the 4 weeks preceding inclusion (6 weeks in the case of nitroso-urea and mitomycin C). * Treatment with drugs under development within 4 weeks. * Cerebral metastases metastasis with the exception of: known metastasis previously treated by surgery or stereotactic radio-surgery, AND Cerebral metastasis, if still present, must be stable for at least 90 days before inclusion and documented with two consecutive MRI or scanner with contrast media, AND, asymptomatic * Existence of any surgical or medical condition which, in the judgment of the Investigator, might interfere with this study. * Patients who are not willing to comply with the provisions of this protocol.